Kalaris Therapeutics, Inc. (KLRS) Stock Price & Analysis
Kalaris Therapeutics, Inc. (KLRS) closed at USD 2.19 on Thursday, October 15, 2026, up 2.82% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 2.13; the Oct 15, 2026 session ranged USD 2.1–2.23 on volume of 56,980 shares. Market capitalization is $52.13M, with a 52-week range of USD 2.1–11.88 (NGM). Source: Nexqual, retrieved October 16, 2026 at 05:20 UTC.
Also available as compact Markdown for AI agents: nexqual.com/KLRS.md
Key facts (KLRS)
- Analysts: Buy (mean 1.88 on a 1–5 scale) (8 analysts), mean target USD 18.71 (range 7–25).
- Total return with dividends: 1Y -54.3% vs S&P 500 +18.1%; 5Y -99.6% vs S&P 500 +85.1%.
Analysts (KLRS)
Consensus Buy (mean 1.88 on a 1–5 scale), 8 analysts; mean target USD 18.71 (low 7, high 25).
Total return (dividends reinvested) (KLRS)
| 1Y (from 2025-10-16) | 5Y (from 2021-10-11) | |
|---|---|---|
| Total return | -54.3% | -99.6% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | -54.4% | -66.3% |
| Volatility (annualized) | 83.2% | 102.4% |
| Max drawdown | -80.6% (Feb 2026→Oct 2026) | -99.6% (Oct 2021→Oct 2026) |
Key Statistics (as of October 16, 2026 at 05:20 UTC)
| Price | USD 2.19 |
|---|---|
| Change | ▲ 2.82% (up) |
| Previous Close | USD 2.13 |
| Open | USD 2.2 |
| Day Range | USD 2.1 – 2.23 |
| 52-Week Range | USD 2.1 – 11.88 |
| Volume | 56,980 shares |
| Market Cap | $52.13M |
| Exchange | NGM |
Technical Analysis (KLRS)
Nexqual's technical model rates KLRS "SELL" based on 2 bullish and 5 bearish signals across 127 daily candles, as of October 16, 2026 at 05:20 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 17.34 (oversold) |
| vs SMA50 | Below (USD 3.4) |
| MACD | -0.35 (negative) |
Analyst Ratings (KLRS)
Wall Street analysts rate KLRS "Buy" based on 8 analysts, with a mean price target of USD 18.71 (range USD 7–25), per Nexqual as of October 16, 2026 at 05:20 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 8 |
| Mean Target | USD 18.71 |
| High Target | USD 25 |
| Low Target | USD 7 |
| Buy / Hold / Sell | 7 / 1 / 0 |
Earnings (KLRS)
| EPS Estimate | USD -0.52 |
|---|---|
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.48 vs est -0.5 ▲ beat |
| 2026-03-31 | USD -0.46 vs est -0.52 ▲ beat |
| 2025-12-31 | USD -0.44 vs est -0.55 ▲ beat |
| 2025-09-30 | USD -0.64 vs est -0.61 ▼ miss |
Source: Nexqual, October 16, 2026 at 05:20 UTC.
Financials & Fundamentals (KLRS)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -79.91% |
| Debt / Equity | 0.02 |
| Current Ratio | 10.98 |
| Total Cash | $93.54M |
| Total Debt | $1.40M |
Source: Nexqual, October 16, 2026 at 05:20 UTC.
Financial Health Score (KLRS)
Nexqual rates Kalaris Therapeutics, Inc.'s overall financial health "Mixed" across five dimensions, as of October 16, 2026 at 05:20 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $94M cash vs $1M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$41M (TTM) |
| Efficiency | Critical — ROE -80%, ROA -31.0% |
Ownership (KLRS)
| Insider Ownership | +8.81% |
|---|---|
| Institutional Ownership | +75.84% |
| Shares Outstanding | 23.80M |
| Float | 7.25M |
| Short % of Float | +3.98% |
Source: Nexqual, October 16, 2026 at 05:20 UTC.
Leadership (KLRS)
Kalaris Therapeutics, Inc. is led by Andrew Oxtoby (age 51), President, CEO & Director, per Nexqual as of October 16, 2026 at 05:20 UTC.
| President, CEO & Director | Andrew Oxtoby (age 51) |
|---|---|
| Director & Co-Founder | Srinivas Akkaraju (age 57) |
| Co-Founder & Director | Michael Philip Dybbs (age 50) |
| Independent Director & Co-Founder | Napoleone Ferrara (age 68) |
| CFO & Treasurer | Liisa Ann Bayko (age 54) |
Major Backers & Investors (KLRS)
Notable institutional backers of Kalaris Therapeutics, Inc. include RTW Investments LP, Alyeska Investment Group, L.p., Siren, L.L.C., according to Nexqual as of October 16, 2026 at 05:20 UTC.
Active Investors
| Investor | Stake |
|---|---|
| RTW Investments LP | 5.46% |
| Alyeska Investment Group, L.p. | 2.41% |
| Siren, L.L.C. | 1.83% |
| Ikarian Capital, LLC | 1.51% |
| UBS Group AG | 1.1% |
| Renaissance Technologies | 0.63% |
| Marshall Wace LLP | 0.58% |
| Fidelity | 0.4% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 3.35% |
| Geode Capital | 0.48% |
Source: Nexqual, October 16, 2026 at 05:20 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 87.97 | ▲ 1.57% |
| BLTE | Belite Bio, Inc | USD 152.62 | ▲ 0.49% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 14.72 | ▲ 1.52% |
| PRAX | Praxis Precision Medicines, Inc | USD 248.24 | ▲ 2.01% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 44.12 | ▲ 4.11% |
| SYRE | Spyre Therapeutics, Inc. | USD 80.1 | ▼ 0.44% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 16, 2026 at 05:20 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt